 Demonstrates statistically significant and clinically meaningful results Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events MACE-4 primary endpoint Presentation of comprehensive data at a key medical conference in the first quarter of 2023 ANN ARBOR, Mich., Dec. ... The post Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL bempedoic acid Meets Primary Endpoint... 